LBPS

4D Pharma (LBPS)

4D Pharma PLC

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LBPS

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2023/01/04	02:10	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/11/16	03:54	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/10/07	23:59	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/10/01	04:04	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/08/25	05:44	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/07/20	00:49	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:LBPS	4D Pharma PLC
2022/07/06	03:07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/06/30	03:26	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/06/29	02:50	Business Wire	4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq	NASDAQ:LBPS	4D Pharma PLC
2022/06/27	21:15	TipRanks	What Made Chardan Capital Downgrade 4d Pharma’s Stock?	NASDAQ:LBPS	4D Pharma PLC
2022/06/25	06:20	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/06/25	04:32	TipRanks	Ladenburg Thalmann & Co. Downgrades 4d Pharma (LBPS) to Hold	NASDAQ:LBPS	4D Pharma PLC
2022/06/25	03:41	Business Wire	Update on Suspension of Trading	NASDAQ:LBPS	4D Pharma PLC
2022/06/24	22:20	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/06/02	04:32	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/05/27	06:30	Business Wire	4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:LBPS	4D Pharma PLC
2022/05/20	05:30	Business Wire	4D pharma to Present at the H.C. Wainwright Global Investment Conference	NASDAQ:LBPS	4D Pharma PLC
2022/05/17	20:00	Business Wire	4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference	NASDAQ:LBPS	4D Pharma PLC
2022/04/29	19:34	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:LBPS	4D Pharma PLC
2022/04/01	06:27	Business Wire	4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022	NASDAQ:LBPS	4D Pharma PLC
2022/03/31	19:25	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:LBPS	4D Pharma PLC
2022/03/29	06:29	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-3/a)	NASDAQ:LBPS	4D Pharma PLC
2022/03/23	20:46	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LBPS	4D Pharma PLC
2022/03/23	20:00	Business Wire	4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma	NASDAQ:LBPS	4D Pharma PLC
2022/03/03	07:26	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:LBPS	4D Pharma PLC
2022/03/01	06:34	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:LBPS	4D Pharma PLC
2022/02/23	21:00	Business Wire	4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit	NASDAQ:LBPS	4D Pharma PLC
2022/02/22	21:00	Business Wire	4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease	NASDAQ:LBPS	4D Pharma PLC
2022/02/19	07:03	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:LBPS	4D Pharma PLC
2022/02/19	07:03	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:LBPS	4D Pharma PLC